Ibrutinib induces a global chromatin reorganisation in chronic lymphocytic leukaemia

Study ID Alternative Stable ID Type
EGAS00001002827 Other

Study Description

Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in developed countries. Ibrutinib (PCI-32765), a specific and irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) represents a major step forward in the treatment of CLL. We have undertaken a detailed analysis of the changes happening to the chromatin structure in CLL cells from patients continuously receiving oral doses of ibrutinib. ChIP-seq has been performed for H3K4me3, H3K27ac, H3K27me3 and EZH2 . We observed that Ibrutinib-dependent lymphocytosis correlates with a global and transient recruitment of EZH2 to active cis-regulatory elements and increased H3K27me3.

Study Datasets 1 dataset.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EZH2, H3K4me3, H3K27ac and H3K27me3 ChIP-seq data consisting of fastq single-end reads from peripheral blood CLL cells
Illumina HiSeq 2000,NextSeq 500 34

Who archives the data?

There are no publications available